retatrutide triple agonist gip glp-1 glucagon phase 3 2025 Eli Lilly's shows promising weight loss results in trial retatrutide triple agonist glp-1 gip
Description
Indication expansion, such as approvals for additional metabolic and cardiovascular conditions, is broadening patient access and driving adoption
Weight loss, whether resulting from disease-related conditions or intentional interventions, has been increasingly recognized as a significant risk factor for compromised skeletal integrity
Conclusions GLP-1RA demonstrated phenotype-specific benefits, improving structural remodeling in HFpEF but showing limited effects in HFrEF
Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children
